Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Journal of International Pharmaceutical Research ; (6): 240-244, 2017.
Article in Chinese | WPRIM | ID: wpr-510951

ABSTRACT

Hydromorphone(HM),appeared in the Chinese market in 2013 is a more potent opioid analgesic than morphine and is used for moderate to severe pain. Micro-invasive drug administration methods,including continuous infusion and patientcon?trolled analgesia(PCA),will provide hopes for controlling the outbreak of pain and improving patients' satisfaction. At present ,hydro?morphone is the most commonly used drug for the treatment of acute pain,chronic pain and cancer pain. However,we should also con?sider the stability and compatibility of hydromorphone in the implantable infusion system that is most commonly used in these patients. The purpose of this paper is to review the clinical application and stability(changes in color,pH and concentration)of hydromor?phone in different infusion systems so as to provide the basis of rational clinical application.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 275-278,279, 2017.
Article in Chinese | WPRIM | ID: wpr-606242

ABSTRACT

Objective To explore the clinical effect of three doses of mifepristone on patients with dysfunc-tional uterine bleeding.Methods 150 patients with dysfunctional uterine bleeding were chosen,and they were randomly divided into 3 groups,including low dose group (50 patients),middle dose group (50 patients)and high dose group (50 patients).All patients adopted routine treatment.On the basis of this,the low dose group received 6.25mg/d mifepristone,the middle dose group received 12.5mg/d mifepristone,the high dose group received 18.25mg/d mifepristone,continued 6 months.The influence of follicle stimulating hormone (FSH),luteinizing hor-mone (LH),estradiol (E),progesterone (P),volume of uterine and endometrail thickness of patients were observed. Results After treatment,the FSH,LH,E and P levels in the three groups were significantly decreased compared with before treatment (FSH:t=4.406,5.329,3.610,LH:t=4.563,6.134,4.455,P=0.000,0.000,0.000;P=0.000, 0.000,0.000;E:t=7.173,6.815,7.018,P=0.000,0.000,0.000;E:t=2.367,6.315,4.351,P=0.020,0.000, 0.000),and the difference were statistically significant (all P0.05 ).Compared with the low dose group,E levels in the middle dose group and high dose group significantly decreased(t=3.850,2.085,P=0.000,0.004).Before and after treatment,the uterine volume among the three groups had no significant difference (P>0.05 ).After treatment,the functional uterine bleeding symptoms were significantly relieved in the three groups,the effective rate was 100%.The recurrence rate of the low dose group was 32%,which was significantly higher than 8%and 10%of the middle dose group and high dose group.The amenorrhea rate of the middle dose group and high dose group(6% and 2%)was significantly lower than that of the low dose group (46%).Conclusion The treatment of 12.5mg/d mifepristone is effectively adapted to patients with dysfunctional uterine bleeding.

SELECTION OF CITATIONS
SEARCH DETAIL